Denosumab
Prolia, Xgeva (denosumab) is an antibody pharmaceutical. Denosumab was first approved as Prolia on 2010-05-26. It is used to treat osteoporotic fractures and postmenopausal osteoporosis in the USA. It has been approved in Europe to treat bone fractures, bone resorption, neoplasm metastasis, and postmenopausal osteoporosis. The pharmaceutical is active against tumor necrosis factor ligand superfamily member 11.
| Trade Name | Prolia, Xgeva |
|---|---|
| Common Name | Denosumab |
| Indication | bone fractures, bone resorption, neoplasm metastasis, osteoporotic fractures, postmenopausal osteoporosis |
| Drug Class | Monoclonal antibodies: fully human, bone target |
